Cargando…

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway

Clinical success of the proteasome inhibitor established bortezomib as one of the most effective drugs in treatment of multiple myeloma (MM). While survival benefit of bortezomib generated new treatment strategies, the primary and secondary resistance of MM cells to bortezomib remains a clinical con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Li, Chen, Jing, Han, Xiaoyan, Zhang, Enfan, Huang, Xi, Guo, Xing, Chen, Qingxiao, Wu, Wenjun, Zheng, Gaofeng, He, Donghua, Zhao, Yi, Yang, Yang, He, Jingsong, Cai, Zhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Higher Education Press 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107487/ https://www.ncbi.nlm.nih.gov/pubmed/29441489 http://dx.doi.org/10.1007/s13238-017-0500-9

Ejemplares similares

BAFF is involved in macrophage-induced bortezomib resistance in myeloma
por: Chen, Jing, et al.
Publicado: (2017)

The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China
por: Chen, Qingxiao, et al.
Publicado: (2022)

TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy
por: Chen, Jing, et al.
Publicado: (2023)

Efficacy of Intermittent, Oral Famciclovir Prophylaxis for Bortezomib-Induced Herpes Zoster in Multiple Myeloma Patients
por: Zheng, Gaofeng, et al.
Publicado: (2022)

The NEDD4‐1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma
por: Huang, Xi, et al.
Publicado: (2019)

NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma
por: Huang, Xi, et al.
Publicado: (2022)

Quercetin induces cell apoptosis of myeloma and displays a synergistic effect with dexamethasone in vitro and in vivo xenograft models
por: He, Donghua, et al.
Publicado: (2016)

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
por: He, Jingsong, et al.
Publicado: (2020)

Interleukin-32α promotes the proliferation of multiple myeloma cells by inducing production of IL-6 in bone marrow stromal cells
por: Lin, Xuanru, et al.
Publicado: (2017)

Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma
por: He, JingSong, et al.
Publicado: (2021)

RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-κB and MAPK signaling pathways
por: Qu, Jianwei, et al.
Publicado: (2021)

High serum IL-17A is associated with bone destruction in newly diagnosed multiple myeloma patients
por: Dong, Mengmeng, et al.
Publicado: (2022)

Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease
por: He, Jingsong, et al.
Publicado: (2018)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
por: Han, Xiaoyan, et al.
Publicado: (2021)

Corrigendum: Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
por: Han, Xiaoyan, et al.
Publicado: (2021)

Analysis of High-Risk Extramedullary Relapse Factors in Newly Diagnosed MM Patients
por: Yue, Xiaoyan, et al.
Publicado: (2022)

HMGB1 knockdown increases MM cell vulnerability by regulating autophagy and DNA damage repair
por: Guo, Xing, et al.
Publicado: (2018)

CCL2 promotes macrophages-associated chemoresistance via MCPIP1 dual catalytic activities in multiple myeloma
por: Xu, Ruyi, et al.
Publicado: (2019)

Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression
por: Cao, Liqin, et al.
Publicado: (2022)

The many substrates and functions of NEDD4-1
por: Huang, Xi, et al.
Publicado: (2019)

Identification of key candidate genes and pathways in multiple myeloma by integrated bioinformatics analysis
por: Yan, Haimeng, et al.
Publicado: (2019)

Residues 240–250 in the C-Terminus of the Pirh2 Protein Complement the Function of the RING Domain in Self-Ubiquitination of the Pirh2 Protein
por: Abou Zeinab, Rami, et al.
Publicado: (2013)

Myeloma-derived IL-32γ induced PD-L1 expression in macrophages facilitates immune escape via the PFKFB3-JAK1 axis
por: Liu, Yang, et al.
Publicado: (2022)

The Role of E3 Ligase Pirh2 in Disease
por: Daks, Alexandra, et al.
Publicado: (2022)

Retraction: Residues 240–250 in the C-Terminus of the Pirh2 Protein Complement the Function of the RING Domain in Self-Ubiquitination of the Pirh2 Protein
Publicado: (2021)

Camalexin Induces Apoptosis via the ROS-ER Stress-Mitochondrial Apoptosis Pathway in AML Cells
por: Yang, Yang, et al.
Publicado: (2018)

Recognition of an Ala-rich C-degron by the E3 ligase Pirh2
por: Wang, Xiaolu, et al.
Publicado: (2023)

Dihydroartemisinin Modulates Apoptosis and Autophagy in Multiple Myeloma through the P38/MAPK and Wnt/β-Catenin Signaling Pathways
por: Wu, Xiuhua, et al.
Publicado: (2020)

Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma
por: Wei, GuoQing, et al.
Publicado: (2017)

Human Pirh2 is A Novel Inhibitor of Prototype Foamy Virus Replication
por: Dong, Lanlan, et al.
Publicado: (2015)

Regulation of p73 by Pirh2-AIP4 loop
por: Wu, H. Helena, et al.
Publicado: (2021)

Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients
por: Dong, Mengmeng, et al.
Publicado: (2022)

Targeting the Non-Canonical NF-κB Pathway in Chronic Lymphocytic Leukemia and Multiple Myeloma
por: Burley, Thomas A., et al.
Publicado: (2022)

The Clinical Characteristics and Prognosis of Chinese Patients with Light-Chain Amyloidosis: A Retrospective Multicenter Analysis
por: He, Donghua, et al.
Publicado: (2021)

Role of Pirh2 in Mediating the Regulation of p53 and c-Myc
por: Hakem, Anne, et al.
Publicado: (2011)

Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells
por: Markovina, Stephanie, et al.
Publicado: (2010)

Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma
por: Han, Xiaoyan, et al.
Publicado: (2017)

Integrated bioinformatic analysis of HNF1A in human cancers
por: Zhang, Enfan, et al.
Publicado: (2021)

Silencing of SENP2 in Multiple Myeloma Induces Bortezomib Resistance by Activating NF-κB Through the Modulation of IκBα Sumoylation
por: Xie, Hongyi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9f549ljj2fnrima6lkmhj4siq9